Emerging therapies for multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emerging therapies for multiple myeloma

Published:2009-02-27 Issue:1 Volume:14 Page:99-127
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Podar Klaus¹,Tai Yu-Tzu¹,Hideshima Teru¹,Vallet Sonia²,Richardson Paul G¹,Anderson Kenneth C¹

Affiliation:

1. Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA ; ;

2. Massachussetts General Hospital (MGH) & Harvard Medical School, Center for Multiple Myeloma, Boston, Massachusetts 02115, USA

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1517/14728210802676278

Reference188 articles.

1. The malignant clone and the bone-marrow environment

2. Multiple myeloma

3. Treatment for Multiple Myeloma

4. The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

5. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma;British Journal of Haematology;2023-12-05

2. Reconciling the Gap between Medications and their Potential Leads: The Role of Marine Metabolites in the Discovery of New Anticancer Drugs: A Comprehensive Review;Current Pharmaceutical Design;2023-11

3. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways;Molecules;2022-05-30

4. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies;European Journal of Pharmacology;2022-04

5. Development, Statistical Optimization and Characterization of Fluvastatin Loaded Solid Lipid Nanoparticles: A 32 Factorial Design Approach;Pharmaceutics;2022-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3